CHISUNGO-671, KEYTRUDA, Merck, NSCLC, Pembrolizumab
Neoadjuvant / adjuvant pembrolizumab inotenderwa neFDA kune inogadziriswa isiri-diki cell kenza yemapapu.
Mbudzi 2023: Pembrolizumab (Keytruda, Merck) yakapihwa mvumo neFood and Drug Administration (FDA) semushonga weoadjuvant wakasanganiswa neplatinum-ine chemotherapy uye seyamushure-kuvhiya adjuvant kurapwa f.
Pembrolizumab, USFDA
Enfortumab vedotin-ejfv ine pembrolizumab inotenderwa neUSFDA kune yemuno advanced kana metastatic urothelial carcinoma.
Kukadzi 2024: Chikafu neDrug Administration yakamhanyisa nzira yekubvumidzwa kwemishonga miviri, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) uye pembrolizumab (Keytruda, Merck). Mishonga iyi inoitirwa kurapa vanhu vemuno..
FDA, Zvokudya uye Drug Administration, KEYTRUDA, Merck, Pembrolizumab, platinum-based chemotherapy
Pembrolizumab inotenderwa neFDA seadjuvant kurapwa kune isiri-diki cell kenza yemapapu.
Kukadzi 2023: Yechikamu IB (T2a 4 cm), nhanho II, kana nhanho IIIA isiri diki cell cancer yemapapu, iyo Food and Drug Administration (FDA) yakabvumidza pembrolizumab (Keytruda, Merck) seadjuvant therapy mushure mekubviswa uye platinamu-based chemoth. ..
KEYTRUDA, Merck, Pembrolizumab, Roche Tissue Diagnostics, Ventana Medical Systems
Pembrolizumab inobvumidzwa kune advanced endometrial carcinoma
Kubvumbi 2022: Pembrolizumab (Keytruda, Merck) yakatenderwa neFood and Drug Administration sechinhu chimwe chete chevarwere vane advanced endometrial carcinoma iri microsatellite instability-high (MSI-H) kana mismatch repair de.
NCT03142334, Pembrolizumab, renal cell carcinoma
Pembrolizumab inotenderwa kurapa adjuvant renal cell carcinoma
Jan 2022: Pembrolizumab (Keytruda, Merck) yakatenderwa neFood and Drug Administration yekurapa adjuvant yevarwere vane renal cell carcinoma (RCC) vari pakati-yakakwirira kana yakanyanya njodzi yekudzokororwa mushure me…
Bevacizumab, KEYTRUDA, Merck, PD-L1, Pembrolizumab
Pembrolizumab musanganiswa unotenderwa neFDA kune yekutanga-mutsara kurapwa kwegomarara remuchibereko
Nov 2021: Pembrolizumab (Keytruda, Merck) yakabatana nechemotherapy, ine kana isina bevacizumab, yakatenderwa neChikafu uye Drug Administration kune varwere vanoramba, vanodzokororwa, kana metastatic cervical cancer.
KEYTRUDA, Merck, Pembrolizumab, TNBC kuwedzera
Pembrolizumab yakagamuchirwa neDFA kune yakanyanya njodzi njodzi-yekutanga katatu-isina kenza yemazamu
Nyamavhuvhu 2021: Pembrolizumab (Keytruda, Merck) yakagamuchirwa neDFA kune yakanyanya njodzi, yekutanga-nhanho katatu-isina kenza yemazamu (TNBC) senge neoadjuvant kurapwa mukubatana nekemotherapy, uye gare gare seimwe chete mumiriri seadjuv ..
Eisai, KEYTRUDA, Lenvatinib, Lenvima, Merck, NCT03517449, Pembrolizumab
Pembrolizumab uye lenvatinib zvakagamuchirwa neDFA yekenza yemakemikari yepamusoro
Nyamavhuvhu 2021: Pembrolizumab (Keytruda, Merck) yakabatana nelenvatinib (Lenvima, Eisai) yakagamuchirwa neKudya neDrug Administration kune varwere vane advanced endometrial carcinoma isiri microsatellite instabi ..
fluoropyrimidine, gastroesophageal junction (GEJ) adenocarcinoma, KEYTRUDA, Merck & Co, Pembrolizumab, Trastuzumab
Pembrolizumab inogamuchira mvumo yekukurumidza kubva kune iyo FDA yeHER2-yakanaka kenza yemudumbu
Nyamavhuvhu 2021: Pembrolizumab (Keytruda, Merck & Co) pamwe chete ne trastuzumab, fluoropyrimidine-, uye platinum ine chemotherapy yakapihwa mvumo yekukurumidza neKudya neDrug Administration kweiyo firs ..
cisplatin, esophageal carcinoma, fluoracil, GEJ, CHISUNGO-590, NCT03189719, Pembrolizumab
Pembrolizumab yakagamuchirwa neDFA yekurapa cancer kana gastroesophageal junction cancer.
Nyamavhuvhu 2021: Pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) pamwe neplatinum uye fluoropyrimidine-based chemotherapy yakatenderwa neKudya neDrug Administration kune varwere vane metastatic kana locall ..